Post Traumatic Stress Disorder Market

Increase cases of PTSD to boost market growth

Additionally, the rise of natural and man-made disasters, such as the COVID-19 pandemic and the Russo-Ukrainian War, continue to drive this case.

Further, growing demand for better treatment options will lead to R&D innovations and the launch of new therapeutic options, creating lucrative opportunities for market growth during the forecast period. For instance, For instance, Otsuka Pharmaceutical Development Inc.’s Brexpiprazole and Zoloft Combination is in phase 3 investigation for PTSD. Furthermore, Jazz Pharmaceuticals’ JZP150, Aptinyx’s NYX-783, and Bionomics’ BNC210 are under phase 2 clinical investigation, and such factors are expected to drive growth in the market over the forecast period. However, side effects associated with treatment for post-traumatic stress disorder are to be expected restrain growth over the forecast period.

Increasing product launches and collaborations among major market players in the treatment of PTSD are expected to drive the growth of the post-traumatic stress disorder treatment market during the forecast period. For example, on March 30, 2022, pharmaceutical company Sun Pharmaceutical Industries Ltd. signed a patent licensing agreement with pharmaceutical company H. Lundbeck to market and distribute its own version of vortioxetine (an antidepressant) in India. This product is approved in over 80 countries including the US, Europe, Canada and Australia.

The Global Post-Traumatic Stress Disorder Market Industry is projected to experience substantial growth in the coming years. With an estimated market value of 18.5 USD Billion in 2024, the industry is expected to reach 31.8 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.05% from 2025 to 2035. Such projections reflect the increasing recognition of PTSD as a critical public health issue, alongside the expanding availability of treatment options. The market's evolution is likely to be influenced by ongoing research, technological advancements, and the growing demand for effective therapeutic interventions.

The growing awareness surrounding Post-Traumatic Stress Disorder (PTSD) is a primary driver of the Global Post-Traumatic Stress Disorder Market Industry. Educational campaigns and advocacy efforts have led to a better understanding of PTSD symptoms and treatment options. For instance, organizations are actively promoting mental health awareness, which has resulted in increased diagnosis rates. As a result, the market is projected to reach 18.5 USD Billion in 2024, reflecting a heightened demand for therapeutic interventions and support services. This awareness not only encourages individuals to seek help but also fosters a supportive environment for those affected by trauma.

Government initiatives aimed at addressing mental health issues, particularly PTSD, are significantly influencing the Global Post-Traumatic Stress Disorder Market Industry. Increased funding for mental health programs and research has led to the development of more effective treatment strategies. For instance, various countries have implemented policies to enhance access to mental health services for veterans and civilians alike. This support not only facilitates early intervention but also encourages the establishment of specialized treatment centers. Consequently, the market is expected to benefit from these initiatives, as they contribute to a more robust infrastructure for addressing PTSD.

Innovations in treatment modalities for PTSD are propelling the Global Post-Traumatic Stress Disorder Market Industry forward. New therapeutic approaches, including cognitive-behavioral therapy, eye movement desensitization and reprocessing, and pharmacological advancements, are enhancing recovery outcomes. The integration of technology, such as virtual reality therapy, is also gaining traction, providing immersive experiences that help patients confront and process traumatic memories. These advancements not only improve patient outcomes but also expand the range of available treatment options. As a result, the market is poised for growth, with a projected compound annual growth rate (CAGR) of 5.05% from 2025 to 2035.

The incidence of trauma-related disorders is on the rise, contributing significantly to the Global Post-Traumatic Stress Disorder Market Industry. Factors such as natural disasters, armed conflicts, and personal traumas have led to a surge in PTSD cases. For example, recent statistics indicate that approximately 7-8% of the population will experience PTSD at some point in their lives. This alarming prevalence underscores the necessity for effective treatment options. Consequently, the market is expected to grow, with projections indicating a value of 31.8 USD Billion by 2035, driven by the increasing need for specialized care and therapeutic solutions.

The growing acceptance of mental health treatment is a crucial driver of the Global Post-Traumatic Stress Disorder Market Industry. Societal stigma surrounding mental health issues has gradually diminished, leading to increased willingness among individuals to seek help. This cultural shift is evident in various demographics, including military personnel and first responders, who are often reluctant to acknowledge their struggles. As acceptance rises, more individuals are likely to pursue treatment for PTSD, thereby expanding the market. This trend aligns with the projected growth of the industry, as it adapts to meet the evolving needs of a more open-minded society.

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Post-Traumatic Stress Disorder market accounted for USD 0.46 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the increasing burden of post-traumatic stress disorder, growth in research and development activities as well as the presence of strong and established market players across the region.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3  POST-TRAUMATIC STRESS DISORDER MARKET SHARE BY REGION 2021 (%)

Source Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Post-Traumatic Stress Disorder market accounts for the second-largest market share due to the increased awareness about therapeutic availability and efficacy, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure, as well as a favorable reimbursement system. Further, the Germany market of post-traumatic stress disorder held the largest market share, and the UK market of post-traumatic stress disorder was the fastest growing market in the European region

The Asia-Pacific Post-Traumatic Stress Disorder Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due rise in the geriatric population and the rise in the number of mental and sexual abuse among adults. Moreover, China market of post-traumatic stress disorder held the largest market share, and the India market of post-traumatic stress disorder was the fastest growing market in the Asia-Pacific region

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of post-traumatic stress disorder to grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Post-Traumatic Stress Disorder industry must offer effective drugs or medications to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the  Post-Traumatic Stress Disorder industry to benefit clients and expand the market sector is to develop and introduce drugs that helps in effective treatment. In recent years, Post-Traumatic Stress Disorder industry has provided medicine with some of the most significant benefits. The Post-Traumatic Stress Disorder market major player such as Mylan NV (US), Greenstone LLC (US), Bionomics (Australia), Tonix Pharmaceuticals Holding Corp. (US), Marinus Pharmaceuticals Inc. (US), Azevan Pharmaceuticals (US), Lundbeck A/S (Denmark), and others are working to expand the market demand by investing in research and development activities.

Bionomics Ltd operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a pipeline of novel therapeutic ion channel targeting drug candidates to improve the lives of patients suffering from central nervous system (CNS) disorders. Bionomics serves customers in Australia. In November 4, 2019, Bionomics limited, a  clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders..

Also, The goal of Tonix, a clinical-stage biopharmaceutical firm, is to find, acquire, licence, and develop therapies to treat, prevent, and lessen pain in humans. Tonix's product pipeline includes candidates for the central nervous system (CNS), uncommon diseases, immunology, and infectious diseases. Small molecules and biologics for the treatment of pain, neurologic, psychiatric, and addiction problems are included in Tonix's CNS portfolio.

TNX-102 SL1 is a potential treatment for a group of individuals with Long COVID syndrome, and Tonix Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported in August 2022 that the first patient has been enrolled in the Phase 2 PREVAIL study of this drug. As a daily bedtime medication for Long COVID, fibromyalgia, PTSD, alcohol use disorder, and agitation in Alzheimer's disease, TNX-102 SL is currently undergoing clinical testing.